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Abstract 
Papillary  serous  carcinoma  of  the  uterine
cervix (PSCC) is a very rare, recently described
variant  of  cervical  adenocarcinoma.  This
review,  describes  a  case  of  stage  IV  PSCC
whose  main  tumor  existed  in  the  uterine
cervix and invaded one third of the inferior
part of the anterior and posterior vaginal walls.
Furthermore,  it  had  metastasized  from  the
para-aortic  lymph  nodes  to  bilateral  neck
lymph nodes. Immnoreactivity for CA125 was
positive, whereas the staining for p53 and WT-
1 were negative in both the original tumor and
the metastatic lymph nodes. Six cycles of pacli-
taxel and carboplatin combination chemother-
apy were administered and the PSCC dramati-
cally decreased in size. The main tumor of the
uterine cervix showed a complete response by
magnetic  resonance  imaging  (MRI),  and  on
rebiopsy, more than 95% of the tumor cells in
the  cervix  had  microscopically  disapperared.
This is the first report of PSCC in which com-
bination chemotherapy was used and showed a
remarkable response.
Introduction
Adenocarcinomas  of  the  uterine  cervix
account for approximately 10-20% of invasive
cervical  carcinomas,  and  the  endocervical
types comprise approximately 70% of adeno-
carcinomas  of  the  uterine  cervix.1 Papillary
serous carcinoma of the cervix (PSCC) is an
uncommon, recently described variant of cervi-
cal  adenocarcinoma  that  is  morphologically
similar  to  papillary  serous  adenocarcinoma
arising from the ovary, uterine endometrium,
fallopian tube and peritoneum. In general, ade-
nocarcinomas of the uterine cervix not only
have  poor  chemosensitivity,  but  also  poor
radiosensitivity.  This  review  describes  an
advanced PSCC case that exhibited a remark-
able  response  to  paclitaxel  and  carboplatin
combination chemotherapy. 
Case Report
A  56-year-old  Japanese  female,  G4  P2,
noticed  a  swollen  lymph  node  in  her  right
neck.  She  visited  an  otolaryngological  clinic
one month later. A lymph node biopsy was per-
formed at this clinic. The pathologic diagnosis
was PSC and was suspected to be metastatic
adenocarcinoma. As she had also experienced
a small amount of postmenopausal bleeding,
she  referred  to  the  outpatient  clinic
(Department of Obstetrics and Gynecology) at
our hospital. During the pelvic examination, a
hard and swollen tumor of the uterine cervix
was detected and had invaded the left and right
parametrium to the pelvic wall as well as inva-
sion to the inferior one third of the anterior
and posterior vaginal walls. We performed a
biopsy  of  the  uterine  tumor  and  obtained  a
diagnosis of PSCC microscopically (Figure 1).
The  tumor  had  a  complex  papillary  pattern
with epithelial stratification and tufting with
the formation of cellular buds. In the nonpapil-
lary parts, the tumor cells had a predominantly
glandular growth pattern. The tumor cells had
>10 mitotic figures per 10 high-power fields
and scattered psammoma bodies. 
Immunoreactivity  for  CA125  was  positive
both in the uterine cervical tumor cells and the
lymph  node  cells.  On  the  other  hand,
immunoreactivity for p53 and Wilms’ tumor-1
(WT-1)  was  negative  for  both  locations
(Table1). The pathologic characteristics of the
right neck lymph node were consistent with
those of the uterine cervix. We diagnosed the
swollen neck lymph node as metastasis from
the  uterine  cervical  adenocarcinoma.  The
serum CA 125 level was elevated at 2480 U/mL
(normal range <35 U/mL). Computed tomogra-
phy (CT) scan revealed the swelling of multi-
ple  lymph  nodes  on  bilateral  sides  of  the
patient’s  neck  (Figure  2).  Furthermore,  it
revealed the swelling of multiple lymph nodes
in her mediastinum and para-aortic and pelvic
lymph nodes. Lung and liver metastases were
not seen. Magnetic resonance imaging (MRI)
showed an enlarged uterine cervical mass and
vaginal invasion to one third of the inferior
parts (Figure 3). However, there was no evi-
dence  of  a  uterine  endometrial  tumor.  The
final clinical diagnosis was stage IVb PSCC. 
We selected a paclitaxel (175 mg/m2) and
carboplatin (AUC 5) combination chemothera-
py  for  the  primary  treatment.  The  patient
received  six  courses  of  this  chemotherapy
after which her CA125 level fell to 45 U/mL.
The tumor had been rapidly reduced in size by
over 95%. CT scan showed an almost complete
response based on the response evaluation cri-
teria  in  solid  tumors  (RECIST).  MRI  also
showed remarkable reduction of the uterine
cervical tumor and vaginal masses (Figure 4).
Re-biopsy of the uterine cervix demonstrated
that nearly all of the carcinoma cells had disap-
peared, except for a small focus of atypical cells
in the cervical stroma (>95% of the malignant
cells had disapperared; Figure 5).
We are planning a debulking surgery for this
patient. If the tumor recurs, we will continue
the chemotherapy.
Discussion
PSCC  is  a  very  rare  specific  subtype  of
endocervical adenocarcinomas.1 To the best of
our knowledge, only 45 cases of PSCC have
been reported (Table 2).2-15 PSCC should be
distinguished  from  other  papillary  carcino-
mas of the cervix, such as low-grade papillary
villoglandular  adenocarcinoma,  a  variant  of
endocrevical  adenocarcinoma  with  a  good
prognosis. In the 45 previously reported cases
of PSCC, some cases were actually villoglan-
dular  adenocarcinomas  or  mixed  types
tumors.9 With regard to our case, the tumors
were composed of papillary tufts and complex
papillae lined by cells with pleomorphic, high-
grade nuclei, numerous mitotic bodies, and
psammmoma  bodies,  which  were  typical  of
PSCC.
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from the ovary, uterine endometrium, fallopian
tube and peritoneum. In our case, the main
tumor existed in the uterine cervix, but the
endometrium was thin. We did not find ovari-
an  masses,  omental  cakes  or  tubal  masses.
Using MRI and CT scans, we diagnosed this
tumor  to  have  originated  from  the  uterine
cervix. By an immunohistochemical analysis,
we examined the expression of CA125, p53 and
WT-1  in  the  tumor.  Our  PSCCs  were
immunopositive  for  CA125,  but  negative  for
p53 and WT-1. Zhou et al reported that 9 of
their  12  (75%)  PSCCs  were  CA125
immunopositive.9 The  p53  immunopositivity
ranged from 42-90% in the previous reports.9,13
Recently, immnunopositivity for p53 has been
reported to be an early event in PSCC, because
p53 expression was detected diffusely in PSCC
in situ.15 It was similar to papillary serous car-
cinomas  of  the  endometrium  (PSCE)16 and
serous  carcinoma  of  the  ovary.17 WT-1  imm-
munostaining has been thought to be useful in
distinguishing serous carcinomas of the ovary,
which  are  mostly  immunopositive  for  WT-1,
from  PSCEs,  which  are  generally  most
immunonegative  for  WT-1.13 Our  PSCC  was
also immunonegative for WT-1. These findings
suggest that our case of papillary serous carci-
nomas arose from the uterine cervix, and was
not a metastasis from the ovary.
With regard to the treatment of PSCC, pri-
mary surgical therapy has been thought to be
preferable to primary radiotherapy in the early
stage.9 Hysterectomy, radical hysterectomy and
trachelectomy have been used as the primary
surgery, followed by postoperative radiothera-
py.9,13 However,  PSCCs  are  aggressive  neo-
plasms  and  usually  found  with  lymph  node
metastases. Occasionally, PSCCs are found at
advanced stages, such as stage III or IV. 
To our knowledge, there were no reports of
the  effect  of  primary  chemotherapy  against
advanced PSCC cases. Therefore, there was no
evidence  of  the  chemosensitivity  of  the  dis-
ease. Our PSCC case was diagnosed at stage
IVb. Therefore, we could not perform primary
surgery, and elected to administer a combina-
tion chemotherapy using paclitaxel and carbo-
platin. We selected this combined regimen as
the first line chemotherapy, because it is cur-
rently the recommended combination used for
the  treatment  of  ovarian  cancers18,19 and  is
known to have good efficacy against serous car-
cinoma of the ovary.20 The recommended dose
for this combination regimen is thought to be
paclitaxel 175 mg/m2 plus carboplatin AUC 6
(maximum dose, 800 mg/body).21 Usually the
general treatment for ovarian cancer should be
repeated for six to eight courses. In this case,
we obtained an excellent response to a combi-
nation therapy with paclitaxel and carboplatin.
Our PSCC had aggressive activity (tumor cells
had  >10  mitotic  figures  per  10  high-power
Table 1. Immunohistochemical expression
of PSCC.
CA125 p53 WT-1
Immunoreactivity +– –
Figure  3.  T2-weighted  sagital  magnetic
resonance  imaging  showed  an  enlarged
uterine cervical mass and vaginal invasion
to one third of the inferior parts (arrows).
Figure  4.  T2-weighted  sagital  magnetic
resonance  imaging    showed  an  almost
complete response based on the response
evaluation criteria after the chemotherapy.
Figure 5. Almost all of the carcinoma cells
had disappeared, except for a small focus
of  atypical  cells  in  the  cervical  stroma
microscopically.
Table 2. Number of patients with PSCC in
previous reports.
Report N. of patients
Marcus (1963)2 1
Lurie et al.(1991)3 1
Gilks and Clement (1992)4 3
Shintaku and Ueda (1993)5 1
Rose and Reale (1993)6 2
Nguyen and Daya (1997)7 4
Zhou et al.(1997)8 (7)
Zhou et al.(1998)9 17
Kaplan et al.(1998)10 1
Geisler et al.(1998)11 1
Batistatou et al.. (2000)12 1
Nofech-Mozes et al.(2006)13 10
Power et al.(2008)14 2
Nofech-Mozes et al.(2009)15 1
Total No. 45
Figure 1. The tumor had a complex papil-
lary  pattern  with  epithelial  stratification
and tufting with the formation of cellular
buds.  In  the  nonpapillary  parts,  the
tumors cells had a predominantly glandu-
lar growth pattern and scattered psammo-
ma bodies.
Figure  2.  A  computed  tomography  scan
revealed  the  swelling  of  multiple  lymph
nodes  on  bilateral  sides  (arrows)  of  the
patient’s neck.
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fields) and good chmosensitivities to paclitaxel
and carboplatin just like serous carcinoma of
the  ovary  .  Induction  of  tumor  cell  death  by
chemotherapeutic agents often occurs in a cell
cycle-dependent  manner.  It  has  also  been
observed  that  several  regulatory  proteins
involved in tumor chemosensitivity and apopto-
sis are expressed periodically during the cell
cycle progression. However, the nature of can-
cer cellular chemosensitivity and mechanisms
of action of anti-cancer drugs in different phas-
es of the cell cycle still remain unknown. In
addition,  clinical  analysis  of  molecular  bio-
markers that predict responses to chemothera-
peutic agents in uterine cervical carcinomas
has not been carried out. When an advanced
case  of  unresectable  PSCC  is  encountered,
however,  we  recommend  the  use  of  primary
paclitaxel  and  carboplatin  combination
chemotherapy, and also believe that this regi-
men can be used as an effective neoadjuvant
chemotherapy to be performed prior to radical
surgery.
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